The U.S. Food and Drug Administration (FDA) announced Wednesday that it will relax certain rules for approving low-cost versions of some high-priced medications, in an effort to speed up access to ...

The U.S. Food and Drug Administration announced it will relax certain rules for approving low-cost versions of some high-priced medications to reduce costs.

The U.S. Food and Drug Administration will take steps to streamline the process to develop generic versions of complex ...

The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative ...

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...

AI and accelerated computing are transforming the bio/pharmaceutical sector by addressing organizational, technological, and ...

Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...

Eva-Maria Hempe, NVIDIA, says bio/pharma must centralize AI strategy, tackle silos, prioritize process integrity, and balance quick wins with long-term drug design goals.

Ajinomoto Bio-Pharma Services and Olon S.p.A. have entered into a strategic partnership to deliver drug substance manufacturing services.

Executives from Eli Lilly, Merck and other companies foresee the FDA's new onshoring proposal being anything from a ...

Company highlights its global expertise and new and expanded capabilities to help biopharma and biotech customers solve global health challenges Thermo Fisher Scientific Inc., the world leader in ...